5 Key Takeaways

• 1

  A mailed intervention led to nearly 50% of older adults reducing or discontinuing long-term sedative use in the YAWNS NB study.

• 2

  The YAWNS NB trial included 565 participants aged ≥ 65 years with an average BZRA use duration of 11.4 years.

• 3

  46.6% of participants in the YAWNS-1 group achieved BZRA discontinuation or dose reduction of at least 25%.

• 4

  Participants in the YAWNS-1 group reported increased adoption of CBTI techniques and modest improvements in sleep outcomes.

• 5

  Among those who discontinued BZRA use, 33% reported withdrawal symptoms, with insomnia being the most common.